SBR00013

Actinomycin D, Fertiglösung

from Streptomyces sp., 2 mg/mL in DMSO

• Synonym(e): Actinomycin D -Lösung aus Streptomyces sp., Actinomycin IV
• Empirische Formel (Hill-System): C₆₂H₈₆N₁₂O₁₆
• CAS-Nummer: 50-76-0
• Molekulargewicht: 1255.42
• UNSPSC-Code: 12352209
• PubChem Substanz-ID: 329824645

Eigenschaften

• Biologische Quelle: Streptomyces sp.
• Qualitätsniveau: 200
• Beschreibung: Ready Made Solution
• Form: liquid
• Lagerbedingungen: protect from light
• Konzentration: 2 mg/mL in DMSO
• Farbe: dark orange
• Wirkungsspektrum von Antibiotika: neoplastics
• Wirkungsweise: DNA synthesis | interferes
• Lagertemp.: −20°C
• InChI: 1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)
• InChIKey: RJURFGZVJUQBHK-UHFFFAOYSA-N

Beschreibung

Anwendung

<ul>
<li><strong>Regulation of Immune Checkpoints in Cancer:</strong> Actinomycin D is pivotal in studying the ADAR-mediated RNA editing processes that regulate PVR immune checkpoints in colorectal cancer, thus demonstrating its crucial role in cancer immunotherapy research and providing insights into novel therapeutic targets (Qian et al., 2024).</li>
<li><strong>Chemotherapy and Immunotherapy Combination:</strong> The use of Actinomycin D in combined chemotherapy highlights its effectiveness in salvaging multi-chemotherapy agent and avelumab resistant choriocarcinoma, showcasing its potential in overcoming resistance to treatment in gynecological cancers (Lehmann et al., 2023).</li>
<li><strong>Advancements in Dental Medicine:</strong> Actinomycin D is used in regulating gene expression crucial for tissue regeneration and repair in dental health and it is also used to determine RNA stability assay (Pan et al., 2023).</li>
<li><strong>Cancer Progression Research:</strong> The study on hypoxia-induced lncRNA in hepatocellular carcinoma progression, where RNA-binding proteins play a critical role, aligns with Actinomycin D′s application in transcriptional inhibition and its influence on mRNA stability, essential for understanding cancer biology and developing targeted therapies (Tuo et al., 2023).</li>
</ul>

Biochem./physiol. Wirkung

Actinomycin D is an antineoplastic antibiotic that inhibits cell proliferation. It is a cytotoxic inducer of apoptosis against tumor cells. The compound inhibits the proliferation of cells in a nonspecific way by forming a stable complex with double-stranded DNA (via deoxyguanosine residues), thus inhibiting DNA-primed RNA synthesis. It also causes single strand breaks in DNA.

Actinomycin D has been shown to be an inhibitor of the minus-strand transfer step in reverse transcription, and is therefore used in studies and suppression of HIV-replication. It has also been shown to suppress programmed cell death of PC12 cells induced by etoposide, an inhibitor of topoisomerase II.

In cell culture, actinomycin D is used as a selection agent. Actinomycin D binding to yeast in ribosomal RNA has been studied. The sensitivity of various strains of E. coli to actinomycin D and the mechanism of binding has been studied. Actinomycin D is also used in molecular biology as a DNA intercalator which blocks the progression of RNA polymerases.

Verpackung

1ML

Vorsicht

Actinomycin D solutions are very sensitive to light.

Angaben zur Herstellung

The 2 mg/mL solution may be further diluted in an appropriate buffer prior to use.

Sicherheitshinweise

• Piktogramme: GHS08
• Signalwort: Danger
• H-Sätze: H350
• P-Sätze: P201 - P202 - P280 - P308 + P313 - P405 - P501
• Gefahreneinstufungen: Carc. 1B
• Lagerklassenschlüssel: 6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• Flammpunkt (°F): 188.6 °F - closed cup
• Flammpunkt (°C): 87 °C - closed cup